NCT02264093已完成1 期
Effects on the Airway Lumen of Single Oral Doses of Talsaclidine (12, 24, 48 and 60 mg) in Combination With a Single Oral Doses of 160 mg Propranolol in Comparison to the Effects of the Monosubstances (60 mg Talsaclidine and 160 mg Propranolol) in Healthy Elderly Male Volunteers (Partially Randomised, Open Label, Intraindividual Comparison)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 主要终点
- Forced expiratory volume in 1 sec (FEV1)
研究概览
简要总结
To investigate the effects on airway lumen of talsaclidine in combination with propranolol and of talsaclidine and propranolol given as monosubstances
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •All participants in the study should be healthy males, range from 50 to 65 years of age and be within +- 20% of their normal weight (Broca-Index).
排除标准
- •Volunteers will be excluded from the study if the result of the medical examination or laboratory tests (especially those which indicate liver malfunction) are judged by the clinical investigator to differ significantly from the normal clinical values
- •Volunteers with blood pressure lower than 120/80 mm Hg or pulse rate below 60 beats/min
- •Volunteers whose blood pressure dropped below 100/60 mm Hg in the pre-test within 80 mg propranolol
- •Volunteers with Raw-values higher than their predicted normal upper limit
- •Volunteers with known gastrointestinal, hepatic , renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Volunteers with disease of the central nervous system (such as epilepsy) or with psychiatric disorders
- •Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
- •Volunteers with chronic or relevant acute infections
- •Volunteers with history of allergy / hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Volunteers who have taken a drug with a long half life (>=24 hours) within at least one month or less than ten half lives of the respective drug before enrolment in the study
- •Volunteers who received any other drugs which might influence the results of the trial during the week prior the start of the study
- •Volunteers who have participated in another study with an investigational drug within the last 2 month preceding this study
- •Volunteers who are unable to refrain from smoking on the study days
- •Volunteers who smoke more than 10 cigarettes (or 3 cigars or pipes) per day
- •Volunteers who drink more than 40 g of alcohol per day
- •Volunteers who are dependent on drugs
- •Volunteers who have donated blood (>=100ml) within the last 4 weeks
- •Volunteers who participated in excessive physical activities (e.g. competitive sports) within the last week before the study
研究组 & 干预措施
Talsaclidine with Propranol
Experimental
干预措施: Propranolol (Drug)
Talsaclidine with Propranol
Experimental
干预措施: Talsaclidine (Drug)
Propranolol
Active Comparator
干预措施: Propranolol (Drug)
Talsaclidine
Active Comparator
干预措施: Talsaclidine (Drug)
结局指标
主要结局
Forced expiratory volume in 1 sec (FEV1)
时间窗: Up to 8 hours after drug administration
Specific conductance (SGaw)
时间窗: Up to 8 hours after drug administration
Airway resistance (Raw)
时间窗: Up to 8 hours after drug administration
次要结局
- Number of participants with adverse events(Up to 8 days after last drug administration)
- tmax (time from dosing to maximum measured concentration of the analyte in plasma)(Up to 12 hours after drug administration)
- AUC (area under the plasma concentration versus time curve)(Up to 12 hours after drug administration)
- Cmax (maximum measured concentration of the analyte in plasma)(Up to 12 hours after drug administration)
- Number of participants with clinically significant findings in vital signs(Up to 8 days after last drug administration)
- Number of participants with clinically significant findings in laboratory tests(Up to 8 days after last drug administration)
研究者
相似试验
招募中
2 期
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPDCOPDCOPD ExacerbationCOPD BronchitisAirway DiseaseImmune System DisorderNCT05507242Asger Sverrild80
进行中（未招募）
1 期
Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of TezepelumabChronic obstructive pulmonary diseaseCTIS2024-511730-12-00Region Hovedstaden80
进行中（未招募）
2 期
Effects of blocking a messaging protein called TSLP (thymic stromal lymphopoietin) on inflammation in the airwaysChronic obstructive pulmonary diseaseRespiratoryISRCTN14181775niversity of Leicester80
进行中（未招募）
1 期
The effect of blocking TSLP signalling on airway inflammation in patients with chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 21.1Level: LLTClassification code 10009032Term: Chronic obstructive lung diseaseSystem Organ Class: 100000004855EUCTR2022-000179-38-DKBispebjerg Hospital80
已完成
3 期
Effect of transtracheal lidocaine and intravenous lidocaine on hemodynamic of PatientsIRCT20141127020112N10Iran University of Medical Sciences82